SCHEMBL21185442

SCHEMBL21185442

CCOC(=O)/C(=N/N)C(=O)Cc1ccc(F)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
CYP1A2 P05177 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 2/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TDP1 Q9NUW8 3/20 0.43
KDM4E B2RXH2 3/20 0.43
GAA P10253 1/20 0.43
POLB P06746 1/20 0.43
APEX1 P27695 1/20 0.43
EGFR P00533 2/20 0.41
ERBB2 P04626 2/20 0.41
CES2 O00748 1/20 0.40
ACHE P22303 1/20 0.40
CES1 P23141 1/20 0.40
RAB9A P51151 3/20 0.40
NPC1 O15118 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22684775 1.00 MAPT (0.49) MAPTCYP1A2MEN1KMT2ALMNA
SCHEMBL22684774 1.00 MAPT (0.49) MAPTCYP1A2MEN1KMT2ALMNA
SCHEMBL22684789 0.88 KMT2A (0.44) MAPTCYP1A2MEN1KMT2ALMNA
SCHEMBL21185429 0.88 KMT2A (0.44) MAPTCYP1A2MEN1KMT2ALMNA
SCHEMBL22684790 0.88 KMT2A (0.44) MAPTCYP1A2MEN1KMT2ALMNA
SCHEMBL5809024 0.83 MAPT (0.54) MAPTCYP1A2MEN1KMT2ALMNA
SCHEMBL2596988 0.80 MAPT (0.51) MAPTCYP1A2MEN1KMT2ALMNA
SCHEMBL29155066 0.80 MAPT (0.41) MAPTCYP1A2MEN1KMT2ALMNA
SCHEMBL21769297 0.78 RAB9A (0.43) MAPTCYP1A2MEN1KMT2ALMNA
SCHEMBL21769296 0.78 MAPT (0.53) MAPTCYP1A2MEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116437918-A Pyrazolopyridine compounds as TAM inhibitors 上海德琪医药科技有限公司 2023-07-14 CN disclosed
WO-2023016296-A1 HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2023-02-16 WO disclosed
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR TRANSTHERA SCIENCES (NANJING), INC. (CN) 2022-03-10 US disclosed
US-20210177828-A1 TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2021-06-17 US disclosed
EP-3741752-A1 TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF Nanjing Transthera Biosciences Co., Ltd. (CN) 2020-11-25 EP disclosed
WO-2019141202-A9 TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF 南京药捷安康生物科技有限公司 2019-08-29 WO disclosed
WO-2019141202-A1 TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF 南京药捷安康生物科技有限公司 2019-07-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220073496-A1 NOVEL QUINOLINE DERIVATIVE INHIBITOR CSF1R, CSF3R, FLT3 MAPT 2342/4885CYP1A2 2757/4885MEN1 1757/4885
US-20210177828-A1 TAM FAMILY KINASE /AND CSF1R KINASE INHIBITOR AND USE THEREOF CSF1R, CSF3R, FLT3 MAPT 3340/4885CYP1A2 4134/4885MEN1 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.